Baxter Regulatory Master Template

First Page		Document Content
Anatomy Health Von Willebrand disease Coagulation Desmopressin Factor VII Adverse drug reaction Moroctocog alfa Haemophilia Coagulation system Medicine		Baxter Regulatory Master Template Add to Reading List Source URL: www.fda.gov. Download Document from Source Website File Size: 511,10 KB Share Document on Facebook

	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1qHpD - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1q38M - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1pMmB - View Document
	13307 FT Factor VII plasma deficient DocID: 1mVEV - View Document
	UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A • DocID: 1kAcN - View Document

	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1qHpD - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1q38M - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1pMmB - View Document
	13307 FT Factor VII plasma deficient DocID: 1mVEV - View Document
	UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A • DocID: 1kAcN - View Document